By Fineline Cube RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.
Financial Forecast Summary | H1 2026
| Metric | H1 2026 Forecast | YoY Change |
|---|---|---|
| Total Revenue | RMB 5.85 billion | +433% (+RMB 4.752B) |
| Net Profit (GAAP) | RMB 4.70 billion | Turnaround from loss |
| Adjusted Net Profit | RMB 4.30 billion | Turnaround from loss |
| Profit Margin | ~80% (GAAP) | Significant improvement |
Revenue Drivers & Growth Catalysts
Core Product Commercial Success
- Telitacicept: Continued strong domestic sales growth of the company’s flagship lupus treatment
- Disitamab Vedotin: Robust performance of the HER2-targeting antibody-drug conjugate in domestic markets
- Commercial Execution: Enhanced market penetration and physician adoption driving sustained volume growth
Strategic Licensing Partnership
- AbbVie Agreement: Exclusive license deal for PD-1/VEGF bispecific antibody RC148
- Territory: AbbVie obtained exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China
- Revenue Impact: Significant upfront and milestone payments contributing to H1 2026 revenue surge
- Strategic Value: Validates RemeGen’s bispecific antibody platform and provides non-dilutive funding for pipeline advancement
Operational Transformation
- Profitability Turnaround: Transition from H1 2025 losses to substantial H1 2026 profits demonstrates successful commercial scaling
- Operating Leverage: High profit margins reflect efficient cost structure and strong pricing power for innovative biologics
- Cash Generation: Robust profitability provides financial flexibility for pipeline investment and strategic initiatives
Strategic Implications
For RemeGen
- Platform Validation: Strong commercial performance validates RemeGen’s proprietary antibody and bispecific platforms
- Financial Strength: Substantial cash generation reduces need for equity financing and enhances strategic optionality
- Pipeline Funding: Internal cash flow can support advancement of next-generation candidates without external dilution
For Chinese Biotech Sector
- Innovation Premium: Demonstrates that truly differentiated Chinese biotech innovations can command premium valuations and generate substantial profits
- Global Partnerships: AbbVie deal highlights international recognition of Chinese biotech innovation quality
- Commercial Maturity: Represents evolution from clinical-stage companies to commercially successful enterprises
The exceptional H1 2026 performance positions RemeGen as one of China’s most successful commercial-stage biotechnology companies, with a proven ability to translate innovative science into substantial shareholder value.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance and business outlook. Actual results may differ materially due to regulatory developments, competitive dynamics, market adoption rates, and partnership execution risks.-Fineline Info & Tech